2,4-diaminopyrimidine derivates as dopamine D4 receptor antagonist

US6159982A · kind A · utility

Assignee

• Janssen Pharmaceutica NA · BE

Inventors

• Jean-Paul René Marie André Bosmans · Rijkevorsel, BE
• Christopher John Love · Deurne, BE
• Guy Rosalia Eugeen Van Lommen · Berlaar, BE

Key dates

• Filing date: Nov 9, 1998
• Grant date: Dec 12, 2000
• Expiry date: Nov 9, 2018

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D405/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention concerns the compounds of formula ##STR1## the N-oxide forms, the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof, wherein Alk is C.sub.1-6 alkanediyl or C.sub.3-6 alkenediyl; R.sup.1 is hydrogen or C.sub.1-4 alkyl; R.sup.2 and R.sup.3 each independently are hydrogen, C.sub.1-6 alkyl or C.sub.3-7 cycloalkyl; or R.sup.2 and R.sup.3 may also be taken together with the nitrogen atom to which they are attached, thus forming a pyrrolidine, a piperidine or a perhydro azepine ring; R.sup.4 is hydrogen or halo; Q is aryl, aryloxy, di(aryl)methyl or heteroaryl; aryl is naphthyl or phenyl, said naphthyl and phenyl may optionally be substituted; and heteroaryl is quinolinyl, isoquinolinyl, pyridinyl, thienyl, indolyl, 2,3-dihydro-1,4-benzodioxinyl, 2,3-dihydro-benzofuranyl or benzodioxolanyl; said heteroaryls may optionally be substituted: it further relates to processes for their preparation, compositions comprising them as well as their use as a medicine; compounds of formula (I) containing a radioactive isotope; a process of marking dopamine D.sub.4 receptor sites; and a process for imaging an organ are disclosed.